July 22, 2018 Bio/Pharma/CRO Licensing, IP, and Legal Life Science Tools

Gyros Protein Technologies and Cygnus Technologies sign licensing and supply agreement

Uppsala, Sweden and Southport, N.C., July 10, 2018: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, and Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, today announced they have signed a licensing and supply agreement. Under the... Read more

July 18, 2018 Cell Analysis Tools Licensing, IP, and Legal Life Science Tools

Takara Bio strengthens its IP position on single cell RNA-seq

MOUNTAIN VIEW, Calif., July 18, 2018 /PRNewswire/ — Takara Bio USA, Inc., (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce that patent JP6336080B—covering the Smart-seq2 method, developed by Rickard Sandberg and exclusively licensed to TBUSA by the Ludwig Institute—has been awarded by the Japan Patent Office. Additional patents regarding the Smart-seq2 technology... Read more

July 16, 2018 Environ, Ag./Food & Bev Licensing, IP, and Legal Product Launch

GE Healthcare launches Omnipaque Oral Solution, a ready-to-drink iodinated contrast medium for computed tomography of the abdomen

Boston, MA, USA –July 16, 2018 – GE Healthcare is launching OmnipaqueTM (iohexol) Oral Solution in the United States, a new, ready-to-drink iodinated contrast medium that can be used to help physicians diagnose medical conditions by improving the diagnostic visualization of the abdominal gastrointestinal tract.  Omnipaque oral solution is indicated for oral use only in... Read more

July 2, 2018 Bio/Pharma/CRO Licensing, IP, and Legal PR/Corporate

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer

Basel, 02 July 2018 Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple... Read more

June 20, 2018 Cell Analysis Tools Environ, Ag./Food & Bev Licensing, IP, and Legal

FDA approves latest generation somatic cell counting tests for raw milk

20. Jun, 2018 Three FOSS instruments have been approved for official use by NCIMS/FDA in the USA:   • Fossomatic 7 for testing total somatic cell count in raw milk   • Fossomatic 7 DC for testing of total somatic cell count in raw milk   • BacSomatic for testing both total somatic cell count and bacteria count in raw milk... Read more

June 15, 2018 Licensing, IP, and Legal Microscopy

Deciphering the story of the solar system

Research reveals meteorites found in Sudan in 2008 are remnants of lost planet Customer Story News In December 2008 a first meteorite fragment was discovered close to a train station called Almahata Sitta – “Station Six” in Arabic – and thus the meteorite was named. Scientists have long theorized that many more fledgling planets once... Read more

June 14, 2018 Licensing, IP, and Legal Product Launch

Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis

Basel, 14 June 2018 Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis OCREVUS may delay the need for a wheelchair by seven years for people with primary progressive multiple sclerosis (PPMS) Longer-term efficacy and safety data are consistent... Read more

June 11, 2018 Licensing, IP, and Legal

Xylem Inc. to participate at the Melius Industrial Tech & Aerospace Forum

RYE BROOK, N.Y.–(BUSINESS WIRE)–Jun. 11, 2018– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its President and Chief Executive Officer Patrick Decker and Senior Director of Investor Relations Matt Latino will participate in the Melius Industrial Tech & Aerospace Forum at... Read more